Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 456,561,536
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 17,235 M
  • EBITDA $ 18,602 M
  • 60-Month Beta 0.42
  • Price/Sales 14.02
  • Price/Cash Flow 34.98
  • Price/Book 26.60

Options Overview Details

View History
  • Implied Volatility 50.04% ( +5.44%)
  • Historical Volatility 23.26%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 50.04% on 11/15/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.92
  • Today's Volume 48,659
  • Volume Avg (30-Day) 37,440
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 418,517
  • Open Int (30-Day) 324,679

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.90
  • Number of Estimates 3
  • High Estimate 0.94
  • Low Estimate 0.87
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +26.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.32 +1.42%
on 11/15/24
119.07 -14.55%
on 10/17/24
-16.07 (-13.64%)
since 10/15/24
3-Month
100.32 +1.42%
on 11/15/24
139.74 -27.19%
on 08/30/24
-35.83 (-26.04%)
since 08/15/24
52-Week
94.73 +7.40%
on 12/11/23
148.15 -31.33%
on 06/25/24
+5.31 (+5.51%)
since 11/15/23

Most Recent Stories

More News
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

VKTX : 49.58 (-7.45%)
NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 101.74 (-3.40%)
GMAB : 20.59 (-2.79%)
LLY : 746.20 (-4.93%)
ABBV : 164.99 (-2.74%)
Trump Names Anti-Vaxxer Robert Kennedy As Health & Human Services Secretary: Here’s What It Means For Healthcare Stocks

Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.

NVO : 101.74 (-3.40%)
IBB : 133.38 (-4.79%)
LLY : 746.20 (-4.93%)
MRNA : 36.85 (-7.34%)
AMGN : 283.61 (-4.16%)
XBI : 91.83 (-5.29%)
PFE : 24.80 (-4.69%)
BNTX : 99.72 (-3.71%)
SNY : 47.97 (+0.31%)
US Port Strike Threatens Supply of Popular Weight-Loss Drugs Ozempic, Wegovy, Mounjaro, and Zepbound

The ongoing US port strike on the East and Gulf coasts is causing significant disruptions to pharmaceutical supply chains, particularly for the popular weight-loss drugs Wegovy, Ozempic, Mounjaro, and...

NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance

Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential

FVRR : 28.04 (-1.75%)
PAYO : 10.37 (+0.39%)
ALAB : 86.45 (-2.31%)
HIMS : 19.32 (-7.34%)
NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
UPWK : 14.91 (-1.26%)
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?

Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong success in recent years, with several new drugs in the pipeline.Register now to see...

NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
AMGN : 283.61 (-4.16%)
BIIB : 159.99 (-2.97%)
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

The good times aren't over, but the peak of the party might be passing.

NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
Is Viking Therapeutics a Buy on the Dip?

Viking stock has slipped more than 20% from its peak.

VKTX : 49.58 (-7.45%)
NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
Investors Like Certainty. Trump's Win Gave Them Some.

We're also talking about Super Micro, Nvidia, and weight loss.

NVDA : 141.98 (-3.26%)
AAPL : 225.00 (-1.41%)
NVO : 101.74 (-3.40%)
SMCI : 18.58 (+3.16%)
HON : 228.99 (-0.73%)
BRK.AX : 0.500 (unch)
AMGN : 283.61 (-4.16%)
UNH : 592.23 (-0.16%)
COIN : 305.85 (+9.69%)
TSLA : 320.72 (+3.07%)
T : 22.68 (+1.93%)
INTC : 24.35 (-2.72%)
How Altimmune Could Grab a Big Chunk of the GLP-1 Market

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
ALT : 7.61 (-9.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 104.63
2nd Resistance Point 103.49
1st Resistance Point 102.61
Last Price 101.74
1st Support Level 100.59
2nd Support Level 99.45
3rd Support Level 98.57

See More

52-Week High 148.15
Fibonacci 61.8% 127.74
Fibonacci 50% 121.44
Fibonacci 38.2% 115.14
Last Price 101.74
52-Week Low 94.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar